Copy
NEWSLETTERS - The Huntington's Disease News
By AICH - Roma Onlus
View this email in your browser
Newsletters 15 Feb 2017
Huntington's disease news
www.newshd.net
Feb. 13  2017
Cellular quality control process could be Huntington’s disease drug target

The loss of motor function and mental acuity associated with Huntington’s disease might be treatable by restoring a cellular quality control process, which Duke Health researchers have identified as a key factor in the degenerative illness.

READ MORE
Gen. 29  2017
Affrontare il rischio genetico e proteggere la speranza

It took place yesterday, January 24, at the Hall of the Gemelli General Hospital in Rome, the presentation of the book Affrontare il rischio genetico e proteggere la speranza in the presence of the co-authors and important representatives of the scientific world:

READ MORE
Feb 12  2017
The benefits of migration, highlighted in Huntington’s disease

Huntingtin, the protein responsible for Huntington’s disease, is fundamentally important for fetuses to develop in the womb, but we don’t know yet exactly what part it plays in this intricate process. Normally, neurons start life deep within the developing brain, 

READ MORE
Gen. 24 2016
What matters most to Huntington’s disease patients? New survey

Symptoms and treatments that most impact the lives of patients and their caregivers reported in the Journal of Huntington’s Disease 

READ MORE
Gen. 13  2016
outliers to understand Huntington’s disease onset and progression

Researchers have long known that patients with a greater number of CAG repeats in their HD gene tend to display motor symptoms sooner than those with fewer CAG repeats. However, this relationship is not perfect. Sometimes HD 

READ MORE
Gen 30, 2017
Vybion Huntington’s Disease Drug Patent receives Track I Status

Vybion, Inc. is pleased to announce that its patent application covering methods of use and composition for INT41 Gene Therapy received Track I status from the USPTO. The INT41 patent application covers several neurodegenerative diseases in addition to Huntington’s 
READ MORE
Copyright © 2017 aichroma, All rights reserved.


Want to change how you receive these emails?
You can update your preferences or unsubscribe from this list

Email Marketing Powered by Mailchimp